

CONTENTS

1. Graft Vessel Disease (GVD) After Heart Transplantation (HTx)	1
<i>Bruno Reichart and Bruno Meiser</i>	
Experimental Results	1
Clinical Results	2
2. Chronic Allograft Arteriopathy: Insights from Experimental Models	7
<i>Robert B. Colvin, Catharine M. Chase, Henry J. Winn and Paul S. Russell</i>	
Introduction	7
Human Allograft Arteriopathy	8
Experimental Models	10
Nonimmunologic Factors	18
Therapy	20
Summary and Future Studies	25
3. Chronic Rejection in Human Allografts	35
<i>Margaret E. Billingham</i>	
Definition	36
The Pathology of GVD	37
Natural History	39
The Prevalence of GVD	40
4. Chronic Rejection in Human Allografts: Clinical Correlations	45
<i>Michael H. Cave, Linda D. Sharpley and John Wallwork</i>	
Risk Factors for COD	46
Conclusions	51
5. Growth Factors, Cell Signaling and the Pathogenesis of Atherosclerosis	53
<i>Elaine W. Raines, Karin Bornfeldt, Michael Skinner and Russell Ross</i>	
Cell Accumulation and the Formation of Lesions of Atherosclerosis ...	53
Growth Factors as Mediators of Cell Accumulation	55
Cellular Context and Its Impact on the Responsiveness of Smooth Muscle Cells to Stimulation by Growth Factors	57
Distinct Signaling Pathways Associated with Cell Migration Versus Proliferation	58
6. Mediator Molecules in Chronic Renal Vascular Rejection	61
<i>Charles E. Alpers, Kelly L. Hudkins and Kevin D. O'Brien</i>	
Growth Factors and Vascular Rejection	64

7. Immune-Vascular Interactions in Atherosclerosis and Transplant Arteriosclerosis	71
<i>Göran K. Hansson</i>	
Introduction	71
Transplant Arteriosclerosis and “Garden Variety” Atherosclerosis	71
Immunopathology of the Atherosclerotic Plaque	73
Mechanisms of Lymphocyte Recruitment in Atherosclerosis	75
Immune Effector Mechanisms and the Pathogenesis of Vascular Disease	77
8. Alterations in Hemostasis, Fibrinolysis and Coagulation in Transplant Vascular Sclerosis	83
<i>W. Page Faulk, Carlos A. Labarrere, David Nelson and Douglas Pitts</i>	
Introduction	83
Materials and Methods	84
Results	85
Discussion	93
9. Modulation of Fibroblastic Cytoskeletal Features During Wound Healing and Fibrosis	101
<i>Giulio Gabbiani</i>	
10. Smooth Muscle Diversity and the Reaction to Injury	107
<i>Cecilia M. Giachelli and Stephen M. Schwartz</i>	
11. Growth Factors as Inducers of Neointimal Hyperplasia	115
<i>David Gordon and Elizabeth G. Nabel</i>	
Effects of Recombinant Growth Factor Expression on Arterial Wall Intimal Development.....	115
Growth Factors and Cell Proliferation in Human Arteries	117
Gene Therapy Approaches to Inhibit Arterial Cell Proliferation	119
Conclusion	121
12. Vascular Extracellular Matrix: Structure, Composition and Function	127
<i>David J. Carey</i>	
Biochemical Composition and Organization of Vascular ECM.....	127
Cellular Interactions with ECM Are Mediated by Transmembrane Receptors.....	129
Regulation of ECM Synthesis and Turnover	131
Accumulation of ECM Is Necessary for VSM Cell Proliferation	132
Roles for Heparan Sulfate Proteoglycans in Regulating VSM Cell Proliferation	133

ECM Accumulation in Animal Models and Human Vascular Disease	135
Summary and Conclusions	135
13. The Structural and Biological Properties of the Transmembrane and Mature Forms of Heparin- Binding EGF-Like Growth Factor	139
<i>Michael Klagsbrun</i>	
Introduction	139
Mature HB-EGF	140
Transmembrane HB-EGF	142
Regulation of HB-EGF Expression	143
Possible Physiological and Pathological Roles of HB-EGF	144
Conclusions	146
14. Cell-Matrix Interactions in Angiogenesis	151
<i>Roberto F. Nicosia</i>	
Abstract.....	151
Introduction	152
The Rat Aorta Model of Angiogenesis: Original Observations	152
The Microvascular ECM: Developmental Changes During Angiogenesis.....	153
Effect of Biomatrix Gels on Rat Aortic Angiogenesis	153
The Serum-Free Rat Aorta Model of Angiogenesis	154
Angiogenic Response of the Rat Aorta: Role of Injury in the Release of Growth Factors	155
The Angiogenic Response of the Rat Aorta Is Due to a Phenotypic Switch of the Intimal Endothelium to a Microvascular Phenotype.....	156
Effect of Basement Membrane Molecules on Rat Aortic Angiogenesis	156
Angiogenesis Is an RGD-Sensitive Process	157
Role of Cell-Cell Interactions in the Perivascular Deposition of Basement Membrane	158
Summary	159
Conclusion.....	159
15. Cytokines as Modulators of Vascular Disease	165
<i>Richard N. Mitchell and Peter Libby</i>	
Cytokines Potentially Involved in Vascular Pathology	166
Evidence Linking Cytokine Expression to In Vivo Pathology	167
Initiating the Vascular Lesions	169

16. Cellular Immunity in Experimental Vascular Sclerosis	175
<i>Charles G. Orosz</i>	
Baseline Information	176
Immunologic Analysis of Long-Term Allograft Survival	178
Considerations and Hypotheses	180
17. The Role of Cytomegalovirus in Transplant Vascular Sclerosis	185
<i>Daniel D. Sedmak</i>	
18. Influence of HLA, Race and Hypertension in the Development of Transplant Vascular Sclerosis	193
<i>Fernando G. Cosio, Michael E. Falkenhain and Ronald M. Ferguson</i>	
19. Impact of the New Immunosuppressives on Chronic Rejection: Potential for Reduction of Graft Injury	201
<i>Philip F. Halloran</i>	
Introduction	201
Understanding the Specific Immune Response	202
The Injury Response	205
Immunosuppression	207
Biological Immunosuppressive Agents for Induction or Treatment of Rejection	211
Synthesis: How Could Immunosuppressive Drugs Affect Chronic Rejection (CR) and Transplant Vascular Sclerosis (TVS)	213
Conclusion	214
20. Immunosuppressive Drugs and Vascular Sclerosis: Cyclosporin and Tacrolimus	219
<i>M.J. Mihatsch, K. Morozumi, E. Kemeny, M. Kyo, Y. Yamaguchi, E.H. Ström, B. Ryffel, F. Gudat and G. Thiel</i>	
Introduction	219
Vascular Lesions Due to Cyclosporin and Tacrolimus	220
Prevalence and Evolution of CAA	220
Regression of CAA	222
Morphological Consequences of Arteriopathy	223
HUS-Like Lesions Due to CSA or FK506	225
Prognostic Significance of Small Vessel Involvement	226
Conclusion	228

21. Summary: Ruminations on Transplant Vascular Sclerosis	231
<i>Pekka Häyry</i>	
Manifestations of Transplant Vascular Sclerosis (TVS)	231
Etiology and Predisposing Factors	232
Inflammation	234
Endothelial Activation	235
SMC Replication and Migration	235
Infection	236
Extracellular Matrix-Smooth Muscle Cell Interactions	237
Reversibility and Contributing Factors	238
Molecules Involved	239
Sites of Therapeutic Intervention	240
Index	243